ArticleFood science & nutrition2026
Aucubin Alleviates Ulcerative Colitis in Mice by Repairing the Intestinal Barrier and Modulating the Microbiota-Metabolism Axis.
Article in Food science & nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a complex pathogenesis, necessitating the development of safe and effective therapeutic interventions. This study aimed to investigate the protective effects and underlying mechanisms of Aucubin (Auc) against dextran sulfate sodium (DSS)-induced UC in mice. Using a DSS-induced colitis model, we systematically evaluated the multifaceted effects of Auc by assessing the Disease Activity Index (DAI), colon length, histopathological changes, immunohistochemical staining, ELISA results, proteomic profiles, 16S rRNA sequencing data, and untargeted metabolomic analyses. Compared with the DSS group, Aucubin high-dose (Auc-H, 100 mg/kg) treatment significantly attenuated DSS-induced body weight loss, DAI score elevation, and colon shortening (all
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.